Human immunoglobulin light chains lambda form amyloid fibrils and granular aggregates in solution.

Area of Science:

• Nephrology
• Biochemistry
• Molecular Biology

Background:

• Myeloma nephropathy involves kidney deposition of monoclonal immunoglobulin light chains.
• These chains form amyloid fibrils or amorphous aggregates.
• The molecular mechanisms behind aggregate formation are not well understood.

Purpose of the Study:

• To investigate the self-association kinetics of human monoclonal immunoglobulin light chains lambda (GRY).
• To understand the distinct molecular pathways leading to different aggregate types in myeloma nephropathy.

Main Methods:

• Isolation and characterization of GRY light chains from patient urine.
• Analysis of aggregation pathways using spectral probe binding, gel filtration, Western blot, and electron microscopy.
• Examination of early-stage oligomers via protein cross-linking.

Main Results:

• GRY dimer aggregation produces either amyloid fibrils or amorphous aggregates based on microenvironmental conditions.
• Amyloid fibril formation occurs in phosphate-buffered saline (PBS) at pH 7.0 or with urea (0.8 M) at pH 6.5.
• Granular aggregates form in acetate buffer at pH 3.5; early amyloid formation involves trimers and tetramers.

Conclusions:

• The microenvironment dictates the aggregation pathway of GRY light chains.
• Understanding these pathways is crucial for elucidating myeloma nephropathy pathogenesis.
• GRY oligomerization dynamics provide insights into initial steps of fibril formation.